CBD science and dosing: how it works, bioavailability, dosing, and what the evidence supports
The short version. CBD modulates the endocannabinoid system (ECS) — not by mimicking THC at CB1 receptors, but via FAAH inhibition (raising anandamide), TRPV1 desensitization, 5-HT1A partial agonism, and NF-κB/Nrf2 anti-inflammatory pathways. Oral bioavailability is 6–19%; a high-fat meal increases absorption 4–5× (Birnbaum 2019, PMID 31526026). Tmax is 3–4 hours with a half-life of 18–32 hours at steady state, meaning once-daily dosing is pharmacologically sound. The central dosing fact from the literature: more is not better. Linares 2019 (PMID 30328956) showed 300 mg outperformed both 150 mg and 600 mg in a single-dose crossover — the inverted-U dose-response is real and under-discussed.
Section 1: How CBD works — the endocannabinoid system
The endocannabinoid system
The endocannabinoid system (ECS) is a lipid-signaling network found in virtually every tissue in the human body. It regulates pain, inflammation, mood, sleep, immune function, appetite, and stress response. The ECS consists of three components: endogenous ligands (endocannabinoids), cannabinoid receptors, and the enzymes that synthesize and degrade endocannabinoids.
The two primary receptors are CB1 and CB2. CB1 receptors are expressed predominantly in the central nervous system — the brain and spinal cord — and mediate pain modulation, mood, memory, and appetite. CB2 receptors are expressed mainly on immune cells (macrophages, T cells, B cells, NK cells, microglia) and in peripheral tissues; their activation generally suppresses inflammatory signaling (Nagarkatti 2009, PMID 19422885).
The two primary endogenous ligands are anandamide (AEA) and 2-arachidonoylglycerol (2-AG). Anandamide is sometimes called the "bliss molecule" — it activates CB1 and CB2 and has analgesic, anxiolytic, and anti-inflammatory effects. Anandamide is degraded by the enzyme FAAH (fatty acid amide hydrolase). 2-AG is a full agonist at both CB1 and CB2 and is degraded by MAGL (monoacylglycerol lipase).
What CBD actually does — mechanisms
A common misconception is that CBD "activates the ECS" the same way THC does. It does not. CBD has very low direct affinity for CB1 and CB2 receptors. The research shows CBD works through several indirect and collateral mechanisms:
| Mechanism | Effect | Relevance |
|---|---|---|
| FAAH inhibition | Raises anandamide levels | Pain, anxiety, inflammation, sleep |
| TRPV1 agonism → desensitization | Reduces neurogenic inflammation and pain sensitization | Chronic pain, OA, neuropathic pain |
| 5-HT1A partial agonism | Modulates serotonin signaling | Anxiety, mood, stress response |
| Allosteric CB1 modulation | Enhances endocannabinoid signaling at CB1 | Pain modulation, neuroprotection |
| NF-κB inhibition / Nrf2 activation | Suppresses inflammatory gene expression; antioxidant | Systemic and local inflammation (Atalay 2019, PMID 31817697) |
Why CBD doesn't get you high
THC produces psychoactive effects by binding as a full agonist at CB1 receptors in the brain's mesolimbic dopamine system. CBD has negligible CB1 agonism — it does not activate that pathway. In fact, at CB1, CBD may function as a negative allosteric modulator, slightly reducing THC's psychoactivity when both are present. This is why high-CBD/low-THC products are non-intoxicating: the mechanism is the absence of direct CB1 agonism, not an active neutralizing effect.
Section 2: Bioavailability by delivery route
Bioavailability — the fraction of a dose that reaches systemic circulation — varies dramatically by delivery route. Understanding this is foundational to sensible dosing. The dose on the label is not the dose your body receives.
| Delivery route | Bioavailability | Tmax | Key notes |
|---|---|---|---|
| Oral (oil / capsule) | ~6–19% | 3–4 hours | Most-studied route; first-pass metabolism reduces bioavailability; fat in meal multiplies absorption 4–5× |
| Sublingual (held 60–90s) | ~6–19% (similar to swallowed) | Slightly faster onset | Partial mucosal absorption before swallowing; overall bioavailability similar to oral; onset may be marginally faster |
| Topical — standard | Negligible systemic | Local; variable | Penetrates skin layers; reaches local soft tissue; does NOT reach deep joints (hip, spine); no meaningful systemic absorption = no drug interactions |
| Nano-emulsion topical (Reclaim NANO) | 3–5× transdermal vs standard | Enhanced local delivery | Smaller particle size improves skin penetration; still subject to tissue-depth limits; local anti-inflammatory effect at joint level |
| Transdermal patch | Slow controlled release | Extended (hours–days) | Useful for steady systemic levels; isolate-based = drug-test-safe; suitable for 24-hour coverage applications |
The single most actionable bioavailability fact
Birnbaum et al. 2019 (PMID 31526026) conducted a pharmacokinetic crossover study comparing CBD absorption after a high-fat meal versus fasting. The high-fat meal increased CBD area under the curve (AUC) by 4–5× and peak concentration (Cmax) by 3–4×. CBD is highly lipophilic — fat in the gut is required for efficient micelle formation and lymphatic absorption. Taking oral CBD on an empty stomach wastes most of the dose. Always take oral CBD with a meal containing fat.
Taylor et al. 2018 (PMID 30374683) established the pharmacokinetic profile of oral CBD: Tmax approximately 3–4 hours post-dose with single administration. With repeated daily dosing, CBD accumulates and the terminal half-life extends to 18–32 hours. This means: (1) once-daily dosing is pharmacologically rational; (2) steady-state takes roughly 4–5 days to achieve; (3) don't judge a dose by day-one experience.
Section 3: Dosing — the inverted-U problem
The most counterintuitive and underappreciated fact in CBD dosing: the dose-response relationship is not linear. More CBD does not reliably produce more effect. The evidence shows an inverted-U (bell-curve) pattern.
Linares et al. 2019 (PMID 30328956)
A single-dose, triple-blind crossover study in 57 healthy volunteers compared 150 mg, 300 mg, and 600 mg CBD versus placebo on anxiety during a simulated public speaking test (SPST). The 300 mg dose produced the greatest anxiolytic effect. The 150 mg dose was similar to placebo. The 600 mg dose was also significantly less effective than 300 mg. The inverted-U curve is the evidence. "More is better" is not what the literature shows.
Practical starting guidance
| Starting population | Starting dose | Rationale |
|---|---|---|
| On prescription medications / autoimmune conditions | 10 mg/day | CYP450 drug interaction risk; conservative start with prescriber coordination |
| General wellness, no Rx medications | 15–25 mg/day | Standard starting range; consistent with most self-report surveys showing benefit |
Titration approach
- Hold each dose for 7–10 days before increasing — allow steady-state accumulation (half-life 18–32h means 4–5 days to plateau)
- Increase in increments of 5–10 mg — small steps allow identification of the personal optimal range
- Allow a minimum 4–6 week trial at a consistent dose before concluding it is ineffective
- Most clinical benefit is reported in the 25–75 mg/day range for wellness applications
- No established upper limit: Iffland 2017 (PMID 28861514) reviewed human trials up to 1500 mg/day without serious adverse effects — but clinical benefit does not scale linearly
Timing
CBD's 18–32 hour half-life with repeated dosing means once-daily administration maintains relatively stable plasma levels. Timing is application-dependent:
- Evening dosing — common for sleep and anxiety applications; takes effect overnight, residual levels through next day
- Morning dosing — preferred for daytime pain or inflammation management; peak effect mid-afternoon
- With your largest meal — always, for oral/sublingual — fat content matters more than time of day
Section 4: Drug interactions — overview
CBD is a clinically relevant inhibitor of several cytochrome P450 enzymes. These enzymes metabolize a large fraction of common medications. When CBD inhibits CYP enzymes, drug plasma levels rise — which can push therapeutic drugs into toxic ranges. Bansal et al. 2023 (PMID 37313955) provides a current overview.
| Enzyme | Examples of drugs affected | Severity |
|---|---|---|
| CYP2C9 | Warfarin, NSAIDs (ibuprofen, naproxen), phenytoin | Severe (warfarin) |
| CYP3A4 | Statins, benzodiazepines, many immunosuppressants, calcium channel blockers | Moderate |
| CYP2C19 | SSRIs (citalopram, escitalopram), PPIs (omeprazole), clopidogrel | Moderate |
| CYP2D6 | Some antidepressants (fluoxetine, paroxetine), opioids (codeine, tramadol), beta-blockers | Moderate |
| UGT enzymes | Morphine, acetaminophen glucuronidation | Low–moderate |
Critical distinction: route matters
Topical CBD produces negligible systemic absorption — and therefore negligible CYP450 inhibition. Drug interaction concerns are specific to oral and sublingual CBD, which reach the bloodstream and the liver. If you are on warfarin, benzodiazepines, SSRIs, or statins and want to use CBD, topical application to affected joints is a substantially lower-risk option than oral CBD — and does not require the same prescriber coordination.
For per-drug interaction detail, dosing adjustments, and monitoring guidance, see the drug interactions hub.
Section 5: How to read a COA — quality basics
A certificate of analysis (COA) is the minimum standard for verifying CBD product quality. It is a third-party lab report that confirms what is — and is not — in your product. Without a COA, you are trusting label claims entirely.
Five things to check on every COA
- Potency match — CBD mg should match label (±10% tolerance is acceptable; >20% variance is a red flag)
- THC <0.3% — federal compliance threshold; anything above warrants a flag
- Pesticide panel — must show tested and passed for the key pesticide categories
- Heavy metals — lead, cadmium, arsenic, mercury below action limits (hemp is a bioaccumulator; soil source matters)
- Batch-specific — the lot number on the report must match the lot number on your product; generic or undated COAs are unreliable
For the complete walkthrough — how to find COAs, decode the cannabinoid panel, identify red flags, and what "accredited lab" means — see the COA guide.
Go deeper — component pages in this pillar
Dosing protocol
The full titration protocol: start low, go slow
Step-by-step titration guide with week-by-week increments, tracking templates, and how to identify your personal optimal dose range.
Read the protocol →Specialized dosing
Modified protocol for people on Rx medications
Lower starting doses, prescriber coordination steps, and drug-interaction considerations for autoimmune patients on biologics, DMARDs, or steroids.
Read the guide →Quality verification
How to read a certificate of analysis
Annotated COA walkthrough: cannabinoid panel, potency verification, THC compliance, pesticide and heavy-metal panels, and what accredited testing means.
Read the guide →Mechanism deep-dive
The inflammation mechanism explainer
NF-κB, CB2 immunomodulation, Th1/Th17 modulation, and why "CBD is anti-inflammatory" needs more precision than it typically gets.
Read the explainer →Frequently asked questions
How does CBD work?
CBD modulates the endocannabinoid system (ECS) indirectly — it has low direct affinity for CB1 and CB2 receptors, unlike THC. Its primary mechanisms include FAAH inhibition (raising anandamide), TRPV1 agonism then desensitization (reducing neurogenic inflammation and pain sensitization), 5-HT1A partial agonism (anxiety and mood), allosteric CB1 modulation (enhancing endocannabinoid signaling), and NF-κB/Nrf2 effects (anti-inflammatory and antioxidant). Because CBD does not significantly activate CB1 the way THC does, it produces no psychoactive effect.
Does taking more CBD do more?
Not necessarily — and this is the most important dosing concept in the literature. Linares et al. 2019 (PMID 30328956) showed 300 mg outperformed both 150 mg and 600 mg in a single-dose crossover for anxiety. This inverted-U dose-response relationship means there is a personal optimal range — above and below it, effect is diminished. "More is better" is not supported by the clinical evidence.
Should I take CBD with food?
Yes — always, for oral or sublingual CBD. Birnbaum et al. 2019 (PMID 31526026) showed a high-fat meal increases CBD area under the curve (AUC) 4–5× and peak concentration 3–4× versus fasting. CBD is highly lipophilic — fat in the gut is required for efficient absorption via lymphatic uptake. Taking oral CBD fasted wastes most of the dose. Food is not a preference; it is a pharmacokinetic requirement.
How long before CBD works?
For oral CBD, peak plasma concentration (Tmax) is approximately 3–4 hours post-dose (Taylor 2018, PMID 30374683). With repeated daily dosing, CBD accumulates — the half-life extends to 18–32 hours, and steady-state is reached in roughly 4–5 days. This is why a minimum 4–6 week trial at a consistent dose is needed before concluding it is ineffective. Single-dose assessments are pharmacologically unreliable.
Does topical CBD cause drug interactions?
Standard topical CBD produces negligible systemic absorption. CBD drug interactions — CYP3A4, CYP2C9, CYP2C19, CYP2D6 inhibition — require systemic blood exposure. Because topical CBD does not meaningfully enter the bloodstream, it does not produce clinically significant CYP inhibition. Drug interaction concerns apply to oral and sublingual CBD only. Topical is a substantially lower-risk option for people on warfarin, benzodiazepines, SSRIs, or statins.
How do I know if my CBD is quality?
A batch-specific COA from an accredited third-party lab is the minimum standard. Check: potency matches label (±10%), THC <0.3%, pesticide panel passed, heavy metals below action limits, and the lot number on the COA matches the lot number on your product. Generic COAs not tied to a specific batch are not meaningful quality verification. See the COA guide for the full checklist.
Related reading
References
- Birnbaum AK et al. (2019). Food effect on pharmacokinetics of cannabidiol oral capsules in adult patients with refractory epilepsy. PMID 31526026
- Taylor L et al. (2018). A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects. PMID 30374683
- Linares IMP et al. (2019). No Acute Effects of Cannabidiol on the Sleep-Wake Cycle of Healthy Subjects: A Randomized, Double-Blind, Placebo-Controlled, Crossover Study [inverted-U dose-response for anxiety at SPST]. PMID 30328956
- Iffland K, Grotenhermen F. (2017). An Update on Safety and Side Effects of Cannabidiol: A Review of Clinical Data and Relevant Animal Studies. PMID 28861514
- Bansal S et al. (2023). CBD and Drug Interactions: An Overview. PMID 37313955
- Nagarkatti P et al. (2009). Cannabinoids as novel anti-inflammatory drugs. PMID 19422885
- Atalay S et al. (2019). Antioxidative and Anti-Inflammatory Properties of Cannabidiol. PMID 31817697